HC Wainwright reaffirmed their neutral rating on shares of Zura Bio (NASDAQ:ZURA - Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.
A number of other research analysts have also recently weighed in on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $26.00 price target on shares of Zura Bio in a research report on Thursday, September 19th. Chardan Capital cut their price objective on shares of Zura Bio from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 8th. Leerink Partnrs upgraded shares of Zura Bio to a "strong-buy" rating in a research note on Monday, November 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zura Bio in a report on Friday, October 18th. Finally, Leerink Partners assumed coverage on shares of Zura Bio in a research report on Monday, November 4th. They issued an "outperform" rating and a $15.00 target price for the company. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zura Bio has an average rating of "Buy" and an average target price of $15.80.
Check Out Our Latest Analysis on Zura Bio
Zura Bio Stock Performance
Shares of NASDAQ ZURA traded up $0.05 during midday trading on Monday, reaching $3.21. 241,961 shares of the stock were exchanged, compared to its average volume of 326,924. The stock has a 50 day moving average price of $4.20 and a 200-day moving average price of $4.11. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35.
Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). On average, equities analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.
Insider Activity at Zura Bio
In other news, Director Someit Sidhu sold 51,728 shares of the company's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. This represents a 2.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.10% of the company's stock.
Institutional Investors Weigh In On Zura Bio
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after buying an additional 5,900 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock worth $165,000 after purchasing an additional 6,412 shares in the last quarter. Forefront Analytics LLC grew its stake in shares of Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock valued at $145,000 after purchasing an additional 7,531 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Zura Bio in the 3rd quarter worth approximately $46,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Zura Bio in the 2nd quarter valued at $43,000. 61.14% of the stock is owned by institutional investors and hedge funds.
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Recommended Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
